

DIGNITANA

Clinically superior scalp cooling




2018

YEAR END REPORT

Contents

Results and financial position	3
CEO comments	5
The company	6
The market	7
Business model	9
The product and product development	10
Financial information	11
Allocation of profits	12
Forward-looking statements	12
Risk factors	12
The share	13
Board assurance	14
Financial figures	
Income Statement – Dignitana Group	15
Balance Sheet – Dignitana Group	16
Changes in Equity – Dignitana Group	18
Statement of Cash Flows – Dignitana Group	19
Income Statement – Dignitana AB, Parent Company	20
Balance Sheet – Dignitana AB, Parent Company	21
Policies for preparation of the financial report	23
Financial calendar	23
Contact information	23



Results and financial position

Significant events during the period

- Sales for the period amounted to 8,772 TSEK, \$971 KUSD, an increase of 34 percent compared to the same period in 2017.
- EBITDA amounted to (2,996) TSEK, (\$335) KUSD, a 72 percent improvement compared to the same period in 2017.
- U.S. annual revenue increased 52 percent over 2017.
- Contracts for 8 units were placed globally.
- Contracts were signed for 13 U.S. locations.
- U.S. fourth quarter revenue increased 18 percent over fourth quarter 2017.
- On 8 October Dignitana announced that Mr. Greg Dingizian, via his Adma Förvaltnings AB investment vehicle, had accumulated 10.4 percent of the outstanding common shares of the company.
- On 14 November Dignitana announced the establishment of a clinical trial at Beijing University Cancer Hospital in conjunction with Konica Minolta.
- In December the company completed rights and directed equity issues providing the Company with approximately SEK 33.8M before issue costs.

Significant events after the period

- Contracts for 6 units have been executed globally.
- Contracts have been signed for 5 U.S. locations.
- As a result of the rights and directed equity issues in December, Dignitana now has 48,599,155 shares registered at Bolagsverket which includes those from the rights offering, directed equity and shares issued to guarantors.



Financial results in brief

Key Ratios

DIGNITANA GROUP	Q4 2018	Q4 2017	Full year 2018	Full year 2017
Net revenues, TSEK	8,703	6,505	33,742	22,941
Total revenues TSEK	8,772	6,539	34,075	23,133
Net profit after financial items, TSEK	(5,105)	(13,094)	(25,846)	(42,355)
Cash and bank balances, TSEK	22,161	1,018	22,161	1,018
Earnings per share before and after dilution, SEK ¹	(0.13)	(0.66)	(0.66)	(2.10)

DIGNITANA AB	Q4 2018	Q4 2017	Full year 2018	Full year 2017
Net revenues, TSEK	6,312	5,069	24,849	18,300
Total revenues TSEK	6,381	5,100	25,392	18,490
Net profit after financial items, TSEK	(5,863)	(12,921)	(25,796)	(42,277)
Cash and bank balances, TSEK	19,519	606	19,519	606

1) Rights offering and directed issue closed first quarter 2019.

CEO comments

Dignitana experienced significant growth and transition in 2018. The company executed on its plan of transferring managerial and product development operations from Sweden to the U.S., streamlined our cost structure, and diversified and grew our revenue streams. We enter 2019 a dramatically different entity – strategically and economically poised to capture the global opportunities ahead of us.

In 2018 the U.S. growth, in conjunction with global sales and new revenue channels from service and maintenance contracts, resulted in fourth quarter revenue of 8,772 TSEK, \$971 KUSD, an increase of 34 percent compared to the same period in 2017.

The development of our next generation device, DigniCap Delta, has commanded significant financial and corporate resources over the past year. The new unit, which is pending FDA clearance, is 54 percent smaller, requires 70-80 percent less staff intervention, and introduces a single-patient cap designed to provide a custom fit and optimal results. Based on extensive customer feedback, we are confident that these product

innovations meet the market needs as we push for scalp cooling to become a standard of care for chemotherapy patients. Our highest priority is the successful launch and integration of DigniCap Delta into the global market.

In an oversubscribed issue the Company received SEK 33.8M before issue costs. This funding supports three objectives: continuing the Company's 2019 operations and growth; enabling the Company to launch the DigniCap Delta; and strengthening the Company's overall financial and operating positions.

Building on the solid foundation already established with our customers around the world, we are expanding Dignitana's footprint in existing and new markets while maintaining the high level of service and clinical expertise that our customers expect. Looking to the future I am confident in our team's ability to capitalize on the tremendous opportunity to provide DigniCap's clinically superior scalp cooling to a much wider market.



William Cronin, CEO
Dignitana AB



The company

Dignitana is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North. The company develops, produces and markets **The DigniCap® Scalp Cooling System**, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. DigniCap has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety and acceptable patient comfort. In 2017 Dignitana received an expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lung and other tissues.





The market

Cancer is a leading cause of death worldwide and the number of people who develop cancer is continuing to increase. According to the World Health Organization, 14.1 million people are diagnosed with cancer annually. One of the most common treatments for cancer is chemotherapy. Globally an estimated 20,000 clinics offer chemotherapy, providing over ten million chemotherapy treatments per year.

The side effects of chemotherapy can make treatment very difficult. As a visible reminder of the disease, hair loss is often identified as one of the most distressing side effects. Physicians estimate that approximately ten percent of patients decline the prescribed chemotherapy out of fear of losing their hair.

Dignitana's DigniCap Scalp Cooling System is primarily used today during the treatment of breast cancer, the most common type of cancer in women worldwide. The World Cancer Research Fund reports over 1.7 million diagnosed cases of breast cancer annually. Dignitana estimates that 60 percent of breast cancer patients can be treated with The DigniCap Scalp Cooling System.

In addition, the American Cancer Society reports that in the U.S. each year approximately one million patients are diagnosed with solid tumor cancers. Many of these patients are on regimens compatible with DigniCap.

The DigniCap Scalp Cooling System was invented in Sweden and has been marketed since 2001. It is now available in Asia, Australia, Europe, North America and South America.

The United States is the leading market for medical devices in the world. The sales model in the U.S. involves diversified revenue sources with pay-per-treatment revenue as the largest contributing source.

Contracts for 13 new U.S. facilities were signed during the fourth quarter of 2018, bringing the total to 117 locations.

Since initiating sales in the U.S., the company has focused on multiple location oncology practices, allowing one site in the group to demonstrate the feasibility and efficacy of the treatment, with additional locations joining later. This strategy is now paying off with several smaller practices expanding, as well as Florida Cancer Specialists recently adding more sites to their master agreement.

The global reach of Dignitana is growing as well, with 8 machines sold directly to facilities in Italy and Spain in the fourth quarter 2018 bringing the year-to-date total to 24 units sold globally.

In April Dignitana acquired the management of DigniCap installations at 70 medical facilities in 11 European countries from Sysmex. At the close of the fourth quarter distribution had grown to 86 locations in the same region. Our team continues to work with these facilities to provide prompt and reliable service and several locations have added service agreements as a result of proactive account management.

Interest in scalp cooling in the Middle East is building and work continues with distributor Tesla Medical Solutions


to finalize the regulatory documentation to enable sales in Saudi Arabia, Oman, Kuwait, Armenia and Egypt. Tesla has, to date, placed DigniCap devices in Iraq, Qatar and United Arab Emirates.

For several years Dignitana has been in discussion with Konica Minolta in preparation for the introduction of DigniCap to the substantial Asian market. Our clinical trial at Beijing University Cancer Hospital is the first step toward commercialization in Asia. This trial represents the first clinical evaluation of scalp cooling on an exclusively Asian population and will provide valuable clinical data to identify and support new market growth opportunities.



Business model

The company has four primary revenue streams: treatment fees to patients (pay-per-treatment using leased machines); machine sales; service agreements; and leasing fees. In the United States the largest opportunity for growth is through the pay-per-treatment model. For global markets that do not have a pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies.





The product and product development

The DigniCap Scalp Cooling System has been clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumor cancers. The current DigniCap model has been on the market since 2009. In addition to occasional software upgrades, recent enhancements to the system include the DigniTherm Click Cap, a product extension engineered to improve ease of use and enhance cap fit to improve patient outcomes. The U.S. launch of the Click Cap was completed in March 2018, and the remainder of 2018 showed a steady increase in utilization as facilities

used the new cap and became familiar with the improvements.

The Company is currently engaged in a significant product development initiative to launch the next generation scalp cooling device called DigniCap Delta. This system is a smaller, single-patient device providing improved ease of use for clinicians and patients. Development of the machine is progressing on schedule and at a rapid pace. The introduction of the new system to the market (pending FDA clearance) is planned for the first six months of 2019.

Financial information

Group revenues are generated by direct sales of systems, pay-per-treatment fees, leased machines, service agreements and other revenue such as spare parts sales. Dignitana Group revenues increased 34 percent from 6,539 TSEK in fourth quarter 2017 to 8,772 TSEK fourth quarter 2018.

Dignitana, Inc. continues to grow quarterly revenue with an 18 percent increase in revenue from the fourth quarter 2017 to fourth quarter 2018. Quarterly growth over the last 9 quarters has averaged 18 percent.


Travel expense, revenue sharing, training, maintenance and other costs have resulted in additional expense related to sales at global sites.

Cost of goods sold includes the cost of finished goods sold during the period. Income arising from the sale of goods is recognized when the goods have been delivered and ownership has been transferred to the buyer. In the U.S. Dignitana does not sell the device directly to the end customer as various lease models are used.


In late December the company received its first payment from the rights offering. Additional proceeds have been received in January 2019.

Dignitana revenues and costs are comprised of different currencies such as U.S. Dollars, Euros, SEK, and other currencies. Foreign exchange translation differences are found on the income statement under results from financial investments.

Revenues Per Quarter – Dignitana, Inc. (USD)



Year over Year Dignitana Group Revenue Growth (TSEK)



Allocation of profits

No dividend will be paid for 2018.

Forward-looking statements

This report may contain statements, estimates or projections that constitute “forward-looking statements”. Generally, the words “believe”, “expect”, “intend”, “estimate”, “anticipate”, “project”, “will” and similar expressions identify forward-looking statements, which

generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Risk factors

An investment in securities is associated with risk. Dignitana’s activities are affected, and may be affected, by a number of factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

Following, without any particular order and without claim to be exhaustive, are some of the risk factors and circumstances which are considered essential for Dignitana’s operations and future development. The risks described are not a conclusive list of the risks to which the Company and its shareholders may be exposed. Additional risks that are not currently known to the Company or that the Company currently does not consider essential may also be of significant importance to Dignitana’s business, financial position and results. Such risks may also cause the Company’s share price to fall sharply and investors may lose all or part of their

investment. In addition to this section, investors should also consider the other information contained in the Prospectus as a whole and implement one general environmental assessment.

The non-conclusive list of the Company’s risks concerns (but are not limited to):

Patents, Key Personnel, Growth Management, Restructuring, Development Costs, Competitors, Capital Bonds, Dependence on Individual Customers, Customers, Authorization and Registration, Chemotherapy Without Side Effects, Distributors and Manufacturers, Profitability and Future Capital Needs, Political Risk, Regulatory or Change of Laws, Disputes and Currency Risks.

For a detailed explanation of these risk factors view the December 2018 Company Prospectus posted at <https://investor.dignitana.com/new-issues/>

The share

The total number of outstanding shares at the close of the period 2018 was 40,548,224.

The share has been listed on Nasdaq First North since 30 November 2011 after having been listed at Aktietorget since June 2009. It is traded under the DIGN ticker.

There are 265,000 warrants in the company. The warrants carry the right to purchase 165,000 shares in the period June 1 to 30, 2019 and 100,000 shares in the period June 1 to 30, 2020 and will, on full exercise, increase the company share capital by SEK 265,000.

Erik Penser Bank is the company's Certified Adviser.

In December the Company completed rights and directed equity issues:

- The rights issue was covered by subscription commitments and guarantees up to 100 percent of the total amount in the issue, corresponding to approximately SEK 24.3M.
- 5,383,686 shares, corresponding to 93 percent of the rights issue, was subscribed for with subscription rights and 408,917 shares, corresponding to approximately 7 percent of the rights issue, was subscribed for without subscription rights.
- In total, 1,517,201 shares were subscribed for without subscription right, implying that the rights issue was subscribed for to approximately 119 percent.
- The Company will receive approximately SEK 33.8M before issue costs.

Largest Shareholders

28 DECEMBER 2018

	Holding	Votes
ADMA FÖRVALTNINGS AB	5,720,000	14.11%
FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION	4,135,634	10.20%
CBLDN-UBS FINANCIAL SERVICES INC	3,736,955	9.22%
EUROSUND AB	3,592,328	8.86%
NORDNET PENSIONS FÖRSÄKRING AB	1,252,941	3.09%
IBKR FINANCIAL SERVICES AG, W-8BENE	1,238,385	3.05%
POURSAMAD, AMIR	1,056,046	2.60%
RÜLF, SEMMY	974,863	2.40%
PERSSON, RUTGER	751,431	1.85%
ML, PIERCE, FENNER & SMITH INC	519,434	1.28%
TOTAL	22,978,017	56.66%
OTHER SHAREHOLDERS	17,570,207	43.34%
TOTAL	40,548,224	100.00%

The ten largest shareholders accounted for 57.67 percent of the total shares and the votes.

source: Euroclear

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 26 February 2019

Dignitana AB (publ) Board of Directors

Thomas Kelly
Chairman

William Cronin
Director and CEO

Mikael Wahlgren
Director and
Deputy Managing Director

Ingrid Atteryd Heiman
Director

This interim report has not
been audited by the company auditors.

Income Statement – Dignitana Group

SEK

DIGNITANA GROUP	Q4 2018	Q4 2017	Full year 2018	Full year 2017
Operating Income				
Revenue	8,703,270	6,504,640	33,742,077	22,940,627
Own work capitalized	–	–	–	14,975
Other income	68,975	34,278	332,827	177,763
Total Operating Income	8,772,245	6,538,918	34,074,904	23,133,365
Cost of Goods Sold				
Goods for Resale	1,458,109	825,331	4,085,592	3,724,858
Gross Profit	7,314,136	5,713,587	29,989,312	19,408,507
Operating expenses				
Operating Expense	6,286,710	8,188,087	26,358,173	28,419,237
Personnel expenses	4,023,438	8,106,523	19,555,853	24,687,021
Other Operating expense	869	9,658	29,160	54,808
Total operating expenses	10,311,018	16,304,268	45,943,187	53,161,066
Operating profit (loss) – EBITDA	(2,996,881)	(10,590,681)	(15,953,874)	(33,752,559)
Depreciation of tangible and intangible assets	2,143,738	2,054,531	8,066,961	6,761,746
Operating profit (loss) after depreciation – EBIT	(5,140,619)	(12,645,212)	(24,020,835)	(40,514,305)
Result from financial investments				
Interest income and similar items	836	65	598,895	1,896
Interest expenses and similar items	(36,244)	(448,920)	(2,423,667)	(1,842,255)
Total income (loss) from financial investments	(35,408)	(448,855)	(1,824,772)	(1,840,359)
Net profit (loss) after financial items	(5,105,211)	(13,094,067)	(25,845,607)	(42,354,664)
Corporate Taxes	175,753	245,244	175,753	245,244
Results for the Period	(5,280,965)	(13,339,311)	(26,021,360)	(42,599,908)
Total shares at the period-end before and after dilution ¹	40,548,224	20,274,112	40,548,224	20,274,112
Average number of shares before and after dilution ¹	40,548,224	20,274,112	39,492,859	20,274,112
Earnings per share before and after dilution ¹	(0.13)	(0.66)	(0.66)	(2.10)

1) no dilution

Balance Sheet – Dignitana Group

SEK

STATEMENT OF FINANCIAL POSITION	2018-12-31	2017-12-31
Fixed Assets		
<u>Intangible assets</u>		
Capitalized expenses for development, net	19,029,429	11,399,905
<u>Tangible assets</u>		
Equipment, tools and installations, net	14,747,076	19,355,859
Total Fixed Assets	33,776,505	30,755,764
Current Assets		
<u>Inventories and similar</u>		
Finished goods and goods for resale	6,308,536	2,567,773
Advance payment to suppliers	–	276,062
	6,308,536	2,843,835
<u>Current Receivables</u>		
Accounts Receivable	7,317,979	2,974,624
Current Tax Assets	88,551	219,880
Other current receivables	9,846,053	42,575,635
Prepaid expenses and accrued income	875,257	1,909,562
	18,127,839	47,679,701
<u>Cash and Bank Balances</u>	22,160,876	1,017,957
Total Current Assets	46,597,251	51,541,493
Total Assets	80,373,757	82,297,257

Balance Sheet – Dignitana Group, continued

SEK

STATEMENT OF FINANCIAL POSITION	2018-12-31	2017-12-31
Equity and Liabilities		
Equity		
<u>Restricted equity</u>		
Share Capital		
(40,528,224 shares par value SEK 1, previous year 20,274,112)	40,548,224	20,274,112
Unregistered share capital	8,050,931	20,274,112
Fund for development expenses	12,899,975	2,635,796
	61,499,130	43,184,020
<u>Non-restricted equity</u>		
Other paid-in capital	19,487,347	50,561,848
Results for the period	(26,021,360)	(42,599,908)
	(6,534,013)	7,961,940
Total Equity	54,965,116	51,145,960
Current Liabilities		
Accounts payable	8,089,438	5,090,671
Other current liabilities	2,327,198	431,425
Liabilities to credit institutions	7,258,983	5,000,000
Accrued expenses and deferred income	4,804,166	9,751,101
Total current liabilities	22,479,785	20,273,197
Long Term Liabilities		
Liabilities to credit Institutions	2,928,856	10,878,100
Total Equity and Liabilities	80,373,757	82,297,257

Changes in Equity – Dignitana Group

SEK

	Full year 2018	Full year 2017
Opening balance	51,145,960	55,870,277
New Share Issue	–	–
Unregistered Share Issue	33,813,912	42,575,635
Issue expenses	(3,971,913)	(4,772,032)
Subscribed warrants	–	124,000
Translation difference on consolidation Results for the period	(1,482)	(52,012)
Results through the end of the period	(26,021,360)	(42,599,908)
Closing balance	54,965,116	51,145,960

Statement of Cash Flows – Dignitana Group

SEK

	Q4 2018	Q4 2017	Full year 2018	Full year 2017
Operating Activities				
Operating income				
before financial items	(5,140,619)	(12,645,212)	(24,020,835)	(40,514,305)
Adjustments for items not affecting cash flows	2,143,738	2,959,870	8,066,961	7,210,315
Interest received	(836)	65	598,895	1,896
Interest paid	36,244	(629,052)	(2,423,667)	(622,412)
Income tax paid	(76,367)	81,011	(51,575)	(105,478)
	(3,037,841)	(10,233,318)	(17,830,221)	(34,029,984)
Changes in inventories	582,819	1,498,132	(3,464,701)	(363,242)
Changes in other current receivables	821,050	172,495	(3,309,049)	(704,973)
Changes in other current liabilities	3,354,688	3,796,791	3,972,605	1,631,606
Cash flows from operating activities	1,720,716	(4,765,900)	(20,631,367)	(33,466,593)
Investing Activities				
Acquisition of fixed assets	(5,875,586)	(4,442,027)	(11,087,702)	(14,411,521)
Cash flows from investing activities	(5,875,586)	(4,442,027)	(11,087,702)	(14,411,521)
Financing Activities				
New share issue ¹	23,966,859	–	66,542,504	–
Issuance costs	(3,353,338)	(290,574)	(7,927,913)	(290,574)
Subscribed warrants	–	–	–	124,000
Long Term Liabilities	1,329,357	4,266,704	(5,690,262)	16,282,187
Cash flows from financial activities	21,942,878	3,976,130	52,924,329	16,115,613
Cash flows in the period	17,788,008	(5,231,797)	21,205,260	(31,762,501)
Cash and cash equivalents at start of the period	4,561,721	6,192,011	1,017,957	32,864,372
Translation difference on cash and cash equivalents	(188,854)	57,743	(62,342)	(83,914)
Cash and cash equivalents Period End	22,160,876	1,017,957	22,160,876	1,017,957

1) The unregistered shares at the end of 2017 were reflected as a current receivable on the balance sheet as of 31 December 2017. Upon receipt of these funds in 2018, the statement of cash flows was updated to reflect the incoming cash from the 2017 share issue in the financing activities section for the full year 2018.

Income Statement – Dignitana AB, Parent Company

SEK

DIGNITANA AB, PARENT COMPANY	Q4 2018	Q4 2017	Full year 2018	Full year 2017
Operating Income				
Revenue	6,312,032	5,069,183	24,848,578	18,300,358
Own work capitalized	–	–	–	14,975
Other income	68,975	31,298	543,547	174,783
Total Operating Income	6,381,007	5,100,481	25,392,126	18,490,116
Cost of Goods Sold				
Goods for Resale	1,458,109	825,331	4,085,592	3,724,858
Gross Profit	4,922,899	4,275,150	21,306,533	14,765,258
Operating expenses				
Other external expenses	8,155,374	10,609,885	34,972,918	36,998,667
Personnel expenses	786,869	4,333,918	3,671,013	11,949,482
Other Operating expense	869	9,658	(125,763)	54,808
Total operating expenses	8,943,113	14,953,461	38,518,168	49,002,957
Operating profit (loss) – EBITDA	(4,020,215)	(10,678,311)	(17,211,634)	(34,237,699)
Depreciation and amortization	2,083,475	2,028,372	7,884,010	6,652,242
Operating profit (loss) after depreciation – EBIT	(6,103,690)	(12,706,683)	(25,095,645)	(40,889,941)
Result from financial investments				
Interest income and similar items	–	–	–	–
Interest expenses and similar items	240,797	(213,894)	(700,415)	(1,387,321)
Total income from financial investments	240,797	(213,894)	(700,415)	(1,387,321)
Net profit (loss) after financial items	(5,862,893)	(12,920,577)	(25,796,060)	(42,277,262)
Corporate Taxes	–	–	–	–
Results for the Period	(5,862,893)	(12,920,577)	(25,796,060)	(42,277,262)

Balance Sheet – Dignitana AB, Parent Company

SEK

STATEMENT OF FINANCIAL POSITION	2018-12-31	2017-12-31
Fixed Assets		
<u>Intangible assets</u>		
Capitalized expenses for development, net	19,011,353	11,399,905
<u>Tangible assets</u>		
Equipment, tools and installations, net	14,229,631	19,153,383
<u>Financial assets</u>		
Participations in group companies	522,094	420,010
Total Fixed Assets	33,763,078	30,973,298
Current Assets		
<u>Inventories and similar</u>		
Finished goods and goods for resale	6,308,536	2,567,773
Advance payment to suppliers	–	276,062
	6,308,536	2,843,835
<u>Current Receivables</u>		
Accounts Receivable	2,130,336	460,788
Current Receivables from group companies	905,822	–
Current Tax Assets	88,551	219,880
Other current receivables	9,846,053	42,575,635
Prepaid expenses and accrued income	450,202	1,251,748
	13,420,965	44,508,051
<u>Cash and Bank Balances</u>	19,519,192	606,356
Total Current Assets	39,248,692	47,958,242
<u>Long Term Loan – group</u>	441,122	411,610
Total Assets	73,452,892	79,343,150

Balance Sheet – Dignitana AB, Parent Company, continued

SEK

STATEMENT OF FINANCIAL POSITION	2018-12-31	2017-12-31
Equity and Liabilities		
Equity		
<u>Restricted equity</u>		
Share Capital		
(40,528,224 shares par value SEK 1, previous year 20,274,112)	40,548,224	20,274,112
Unregistered share capital	8,050,931	20,274,112
Fund for development expenses	12,899,975	2,635,796
	61,499,130	43,184,020
<u>Non-restricted equity</u>		
Retained Earnings	(19,705,674)	32,835,766
Share premium reserves	48,064,504	22,301,523
Issue expense	(8,743,945)	(4,772,032)
Results for the period	(25,796,060)	(42,277,262)
	(6,181,175)	8,087,995
Total Equity	55,317,955	51,272,015
Current Liabilities		
Accounts payable	5,678,280	4,409,253
Other current liabilities	–	9,485,220
Liabilities to credit institutions	–	5,000,000
Current payable to group company	7,374,249	431,425
Accrued expenses and deferred income	4,054,879	8,745,237
Total current liabilities	17,107,408	28,071,135
Long Term Liabilities		
Liabilities to Credit Institutions	1,027,530	–
Total Equity and Liabilities	73,452,892	79,343,150

Policies for preparation of the financial report

Swedish Annual Accounts Act (1995:1554) and Swedish Accounting Standards Board General Recommendations BFNAR 2012:1 Annual reporting and consolidated financial statements.

Financial calendar

12 April 2019	2018 Annual Report
15 May 2019	Annual General Meeting
16 May 2019	Q1 Interim Report through 31 March 2019
22 August 2019	Q2 Interim Report through 30 June 2019
21 November 2019	Q3 Interim Report through 30 September 2019
25 February 2020	2019 Year End Report
13 May 2020	Annual General Meeting

All financial reports are available at **www.dignitana.se**

Contact information

Dignitana AB

Traktorgården 3, 226 60 Lund
+46 (0) 46-16 30 90
www.dignitana.se
info@dignitana.se
investorrelations@dignitana.com

Certified Adviser

Erik Penser Bank AB
+46 (0) 8 463 83 00
certifiedadviser@penser.se
www.penser.se